Published by Peptide Protocols · Reviewed September 2026 · How we make these pages · Educational & research purposes only — not medical advice.
If you started a GLP-1 during the great shortage of 2023–2024, there's a decent chance you got a compounded version — cheaper, easier to find, and, for a while, completely above-board. Then the rules changed. If you've been confused about what's legal, what's not, and why your telehealth provider suddenly got cagey, here's the plain-English 2026 map.
During the shortage, compounded semaglutide and tirzepatide filled a real gap. But “allowed because of a shortage” comes with an obvious expiration date: the moment the shortage ends.
A few narrow lanes still exist (for example, genuinely personalized formulations for a documented clinical need — not just a cheaper knock-off of the standard drug). But the broad “get compounded semaglutide because it's cheaper” era is over. If a website is still selling bulk compounded GLP-1s like nothing changed, that's a red flag worth a hard look, not a bargain worth grabbing.
Vial mg + bacteriostatic water mL + your target mcg → mL and U-100 syringe units, instantly. Free, no sign-up, 60+ research peptides preset — plus dedicated calculators and BAC-water charts for BPC-157, retatrutide, tirzepatide, semaglutide, tesamorelin and CJC-1295/ipamorelin.
Open the free peptide calculator →Research & educational use only — never medical advice.
Compounded GLP-1s were a legitimate shortage-era bridge. That bridge is closing. In 2026, the safest, simplest read is: the mass-compounded-copy route is largely gone, the brand-name products are back in normal supply, and the new oral options (like orforglipron) are expanding the legitimate menu. If you're sourcing anything outside a pharmacy for research, transparency and third-party testing aren't nice-to-haves — they're the whole decision.
Routine large-scale compounding of copycat semaglutide is no longer permitted. The shortage was resolved in February 2025, grace periods ended that spring, and in 2026 the FDA moved to exclude it from the 503B bulks list. Enforcement is active. Narrow personalized-need exceptions are a separate, limited matter.
Federal rules let compounders make copies of drugs that are in official FDA shortage. Semaglutide and tirzepatide were on the shortage list during 2023–2024; once the FDA declared the shortages resolved, that permission wound down.
No — but it's outside the brand-name manufacturing and testing pipeline, so quality depends entirely on the specific pharmacy or source. That's exactly why transparency and independent testing matter so much once you leave the standard product.
Brand-name GLP-1s are back in normal supply, and new approved orals like orforglipron are expanding choices. Anything else is a conversation for a licensed clinician — and, for research, a source that publishes its testing.
The Universal Logbook and reconstitution tools keep your notes clean and the math done for you across any compound you study.
Browse the shop on Etsy →We do not recommend or partner with any peptide supplier. Use the checklist instead: third-party COAs that match your batch and lot, stated purity, clear research-use labeling, real support and proper cold-chain shipping.
The supplier checklist →Educational content only. Confirm the legal status where you live before ordering anything.
The one formula, a BAC-water chart, and the 10 most-researched beginner peptides — the math done for you. Print it for the fridge.
🎁 Send me the free cheat sheet →